Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KPTI - Karyopharm Therapeutics Inc


IEX Last Trade
0.7593
-0.012   -1.515%

Share volume: 481,269
Last Updated: Fri 30 Aug 2024 09:53:18 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.77
-0.01
-1.49%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
41%
Profitability 50%
Dept financing 25%
Liquidity 67%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-8.79%
1 Month
-28.28%
3 Months
-19.83%
6 Months
-42.84%
1 Year
-44.51%
2 Year
-84.92%
Key data
Stock price
$0.76
P/E Ratio 
-1.05
DAY RANGE
N/A - N/A
EPS 
-$0.72
52 WEEK RANGE
$0.62 - $1.95
52 WEEK CHANGE
-$0.44
MARKET CAP 
94.785 M
YIELD 
N/A
SHARES OUTSTANDING 
124.684 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.42
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$423,022
AVERAGE 30 VOLUME 
$535,445
Company detail
CEO: Michael Kauffman
Region: US
Website: https://karyopharm.com/
Employees: 506
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Recent news